Filing Flows › Taysha Gene Therapies (TSHA) › R&D spending
Taysha Gene Therapies (TSHA) R&D spending by quarter
Taysha Gene Therapies' R&D spending was $25.0M in Q4 2025 (fourth quarter 2025), +24% from Q2 2025. Over the last 4 quarters it ranged from $15.3M (Q4 2024) to $25.0M (Q4 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q4 2025 | $25.0M | +24% | +63% |
| Q2 2025 | $20.1M | +29% | — |
| Q1 2025 | $15.6M | +2% | — |
| Q4 2024 | $15.3M | — | — |
Q4 2025 at a glance
Taysha Gene Therapies, Q4 2025: revenue $5.5M (+171% year over year), operating margin -516.0%, net loss $27.9M, operating cash flow −$26.7M. The chart follows the revenue to costs, profit and cash.
Questions
What is Taysha Gene Therapies' R&D spending?
Taysha Gene Therapies' R&D spending was $25.0M in Q4 2025 (fourth quarter 2025), +24% from Q2 2025.
How has Taysha Gene Therapies' R&D spending changed?
Over the last 4 quarters it ranged from $15.3M (Q4 2024) to $25.0M (Q4 2025).